Experienced in DICER1 Syndrome

Dr. Carolyn M. Matthews

Gynecologic Oncology | Oncology | Palliative Medicine
Uva Community Health Medical Group LLC
15195 Heathcote Blvd, Suite 320, 
Haymarket, VA 
Accepting New Patients
Offers Telehealth
Experienced in DICER1 Syndrome
Uva Community Health Medical Group LLC
15195 Heathcote Blvd, Suite 320, 
Haymarket, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carolyn Matthews is a Gynecologic Oncologist and an Oncologist in Haymarket, Virginia. Dr. Matthews is rated as an Experienced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Endometrial Cancer, and Ovarian Cancer. Dr. Matthews is currently accepting new patients.

Her clinical research consists of co-authoring 11 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Palliative Medicine
Licenses
Obstetrics & Gynecology in TX
Hospital Affiliations
Novant Prince William Medical Center
Uva Health Haymarket Medical Center
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Innovation Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

UVA COMMUNITY HEALTH MEDICAL GROUP LLC
15195 Heathcote Blvd, Suite 320, Haymarket, VA 20169

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2025
Intervention Type: Drug
Study Drugs: Alpelisib, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes
A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes
Enrollment Status: Completed
Publish Date: September 02, 2020
Intervention Type: Radiation, Drug, Biological, Other
Study Phase: Phase 1
View 4 Less Clinical Trials

11 Total Publications

TNFR2 is Expressed by a Discrete Subset of Epidermal γδ T Cells with an IL-17 Gene Signature during Psoriasis.
TNFR2 is Expressed by a Discrete Subset of Epidermal γδ T Cells with an IL-17 Gene Signature during Psoriasis.
Journal: bioRxiv : the preprint server for biology
Published: September 18, 2025
Similar Doctors
Experienced in DICER1 Syndrome
Dr. Patrick J. Mansky
Oncology | Pediatric Hematology Oncology
Experienced in DICER1 Syndrome
Dr. Patrick J. Mansky
Oncology | Pediatric Hematology Oncology

Frederick Health Hospital Inc

7211 Bank Ct, 
Frederick, MD 
 (40.7 miles away)
240-215-6310
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Mansky is an Oncologist and a Pediatric Hematologist Oncology provider in Frederick, Maryland. Dr. Mansky is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Melanoma. Dr. Mansky is currently accepting new patients.

Experienced in DICER1 Syndrome
Dr. Nicholas C. Lambrou
Gynecologic Oncology | Obstetrics and Gynecology
Experienced in DICER1 Syndrome
Dr. Nicholas C. Lambrou
Gynecologic Oncology | Obstetrics and Gynecology

Luminis Health Medical Group, LLC

2003 Medical Pkwy, Suite 301, 
Annapolis, MD 
 (60.7 miles away)
443-481-3356
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicholas Lambrou is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Annapolis, Maryland. Dr. Lambrou is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Polyps, Testicular Yolk Sac Tumor, Ovarian Carcinosarcoma, and Oophorectomy. Dr. Lambrou is currently accepting new patients.

Experienced in DICER1 Syndrome
Dr. Raj P. Manchandani
Hematology | Oncology | Hematology Oncology
Experienced in DICER1 Syndrome
Dr. Raj P. Manchandani
Hematology | Oncology | Hematology Oncology

Loudoun Medical Group, PC

1860 Town Ctr Dr, Suite 120, 
Reston, VA 
 (17.7 miles away)
703-656-9805
Languages Spoken:
English, Hindi, Sindhi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Raj Manchandani is a Hematologist and an Oncologist in Reston, Virginia. Dr. Manchandani is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Mycosis Fungoides, Anemia, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Manchandani is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Matthews's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile